Nine years ago, a half-dozen professors at Yale and other universities envisioned a life sciences system that would aid researchers and drugmakers in evaluating how patients would respond to a treatment by pulling more information from individual cells.
Today, the idea has grown into Branford-based IsoPlexis, a medical technology company that has expanded from about 40 employees in 2017 to 250, about 150 in Connecticut — with plans to double its workforce in the next few years.